These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1146 related articles for article (PubMed ID: 17675327)
1. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327 [TBL] [Abstract][Full Text] [Related]
2. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223 [TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796 [TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin: a new marker for Crohn's disease? Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438 [TBL] [Abstract][Full Text] [Related]
6. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Leach ST; Yang Z; Messina I; Song C; Geczy CL; Cunningham AM; Day AS Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869 [TBL] [Abstract][Full Text] [Related]
7. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
9. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068 [TBL] [Abstract][Full Text] [Related]
10. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Schröder O; Naumann M; Shastri Y; Povse N; Stein J Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510 [TBL] [Abstract][Full Text] [Related]
12. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166 [TBL] [Abstract][Full Text] [Related]
13. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. Sydora MJ; Sydora BC; Fedorak RN J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175 [TBL] [Abstract][Full Text] [Related]
14. Faecal calprotectin concentrations in gastrointestinal diseases. Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365 [TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419 [TBL] [Abstract][Full Text] [Related]
16. What is the faecal calprotectin test? Drug Ther Bull; 2014 Sep; 52(9):102-4. PubMed ID: 25213590 [TBL] [Abstract][Full Text] [Related]
17. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Sidler MA; Leach ST; Day AS Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298 [TBL] [Abstract][Full Text] [Related]
18. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461 [TBL] [Abstract][Full Text] [Related]
19. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294 [TBL] [Abstract][Full Text] [Related]
20. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Gisbert JP; McNicholl AG Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]